Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms

Immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers, including malignancies once considered untreatable. These agents, however, are associated with inflammation and tissue damage in multiple organs. Myocarditis has emerged as a serious ICI-associated toxicity, becau...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Journal of clinical investigation Ročník 131; číslo 5; s. 1 - 11
Hlavní autori:	Moslehi, Javid, Lichtman, Andrew H., Sharpe, Arlene H., Galluzzi, Lorenzo, Kitsis, Richard N.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States American Society for Clinical Investigation 01.03.2021
Predmet:	Antigens Apoptosis Biomarkers Biomedical research Cancer Cell injury Complications and side effects Cytokines Cytotoxicity Development and progression Drug therapy Enzyme inhibitors FDA approval Heart diseases Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use Immune system Inflammation Ligands Lymphocytes Lymphocytes T Myocarditis Myocarditis - chemically induced Myocarditis - diagnosis Myocarditis - immunology Myocarditis - pathology Peptides Proteins Review T cell receptors Thymus gland Toxicity United States
ISSN:	0021-9738, 1558-8238, 1558-8238
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!